Benzinga | May 5, 2021 06:45AM EDT

Stifel Downgrades Esperion Therapeutics to Hold, Lowers Price Target to $20

Stifel analyst Derek Archila downgrades Esperion Therapeutics (NASDAQ:ESPR) from Buy to Hold and lowers the price target from $37 to $20.